1. Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models
- Author
-
Kathleen Sprouffske, Grainne Kerr, Cheng Li, Anirudh Prahallad, Ramona Rebmann, Verena Waehle, Ulrike Naumann, Hans Bitter, Michael R Jensen, Francesco Hofmann, Saskia M Brachmann, Stéphane Ferretti, and Audrey Kauffmann
- Subjects
Heterogeneity ,Clonal evolution ,Breast cancer ,Metastasis ,Patient derived xenograft models ,Biotechnology ,TP248.13-248.65 - Abstract
Genetic heterogeneity within a tumor arises by clonal evolution, and patients with highly heterogeneous tumors are more likely to be resistant to therapy and have reduced survival. Clonal evolution also occurs when a subset of cells leave the primary tumor to form metastases, which leads to reduced genetic heterogeneity at the metastatic site. Although this process has been observed in human cancer, experimental models which recapitulate this process are lacking. Patient-derived tumor xenografts (PDX) have been shown to recapitulate the patient’s original tumor’s intra-tumor genetic heterogeneity, as well as its genomics and response to treatment, but whether they can be used to model clonal evolution in the metastatic process is currently unknown. Here, we address this question by following genetic changes in two breast cancer PDX models during metastasis. First, we discovered that mouse stroma can be a confounding factor in assessing intra-tumor heterogeneity by whole exome sequencing, thus we developed a new bioinformatic approach to correct for this. Finally, in a spontaneous, but not experimental (tail-vein) metastasis model we observed a loss of heterogeneity in PDX metastases compared to their orthotopic “primary” tumors, confirming that PDX models can faithfully mimic the clonal evolution process undergone in human patients during metastatic spreading.
- Published
- 2020
- Full Text
- View/download PDF